Finance

Beta
Lists
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
$14.92
-0.33%
(-0.050) 1D
$14.92
0.00% (0.00)
After hours
Closed: Jul 15, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
$14.94
High
$15.29
Low
$14.71
Mkt. cap
1.25B
Avg. vol.
1.44M
Volume
878.14K
52-wk high
$26.95
52-wk low
$3.96
EPS
-$0.53
Beta
0.82
Shares outstanding
84.09M
No. of employees
37
Open
$14.94
High
$15.29
Low
$14.71
Mkt. cap
1.25B
Avg. vol.
1.44M
Volume
878.14K
52-wk high
$26.95
52-wk low
$3.96
EPS
-$0.53
Beta
0.82
Shares outstanding
84.09M
No. of employees
37
News stories
From sources across the web
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorBiotechnology
Websitecorvuspharma.com
Analyst ratings
Based on 5 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current $14.92
$40.00 (+168.10%)
Average
$31.60 (+111.80%)
Lowest
$27.00 (+80.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Lee CFA
H.C. Wainwright
Buy
Reiterated
$27.00
+81%
07/01/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$30.00
+101.1%
06/12/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$33.00
+121.2%
05/15/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$40.00
+168.1%
05/14/2026
Etzer Darout
Barclays
Buy
Maintained
$28.00
+87.7%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.87M
8.45M
9.94M
11.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.39M
2.12M
2.28M
3.70M
Operating expense
10.26M
10.57M
12.22M
14.88M
Total operating expenses
10.26M
10.57M
12.22M
14.88M
Operating income
-10.26M
-10.57M
-12.22M
-14.88M
Other non operating income
2.01M
-
-
-
EBT including unusual items
-8.00M
-10.16M
-12.32M
-13.69M
EBT excluding unusual items
-8.00M
-10.16M
-12.32M
-13.69M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.00M
-10.16M
-12.32M
-13.69M
Net profit margin
-
-
-
-
Earnings per share
-0.13
-0.12
-0.15
-0.15
Interest and investment income
639.00K
738.00K
603.00K
1.78M
Interest expense
-
-
-
-
Net interest expenses
639.00K
738.00K
603.00K
1.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.23M
-10.54M
-12.19M
-14.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer